Business
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. Members
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023.\n\n\nMembers of Ligand’s senior management team will provide an update on the company’s strategy and portfolio as well as a multi-year financial outlook and a 2024 guidance preview. The in-person event will be held at the Harvard Club in New York City from 10:30am – 12:00pm. Analysts and investors may register for the event by clicking here. A live and archived webcast will also be available for those unable to attend in person at investor.ligand.com/.\n\n\nPresenters will include:\n\n\n\nTodd Davis, Chief Executive Officer\n\n\n\nMatt Korenberg, President and Chief Operating Officer\n\n\n\nTavo Espinoza, Chief Financial Officer\n\n\n\nPaul Hadden, Senior Vice President, Investments and Business Development\n\n\n\nLauren Hay, Vice President, Strategic Planning and Investment Analytics\n\n\n\nAbout Ligand Pharmaceuticals\n\n\nLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model generates value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.\n\n\nFollow Ligand...